USNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
USNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Usana Health Sciences's book value per share for the quarter that ended in Dec. 2023 was $25.99.
During the past 12 months, Usana Health Sciences's average Book Value Per Share Growth Rate was 14.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 7.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 9.60% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Usana Health Sciences was 77.70% per year. The lowest was -13.30% per year. And the median was 13.90% per year.
Usana Health Sciences's current price is $44.75. Its book value per share for the quarter that ended in Dec. 2023 was $25.99. Hence, today's PB Ratio of Usana Health Sciences is 1.72.
During the past 13 years, the highest P/B Ratio of Usana Health Sciences was 7.48. The lowest was 1.69. And the median was 4.70.
Good Sign:
Usana Health Sciences Inc stock PB Ratio (=1.7) is close to 10-year low of 1.69
The historical data trend for Usana Health Sciences's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Usana Health Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Book Value per Share | Get a 7-Day Free Trial | 16.24 | 20.99 | 20.38 | 22.62 | 25.99 |
Usana Health Sciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Book Value per Share | Get a 7-Day Free Trial | 22.62 | 23.60 | 24.29 | 24.60 | 25.99 |
For the Packaged Foods subindustry, Usana Health Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Usana Health Sciences's PB Ratio falls into.
Usana Health Sciences's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (497.2 | - | 0.0) | / | 19.1 | |
= | 25.99 |
Usana Health Sciences's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (497.2 | - | 0.0) | / | 19.1 | |
= | 25.99 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Usana Health Sciences (NYSE:USNA) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of Usana Health Sciences's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
John Turman Fleming | director | 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120 |
Gilbert A Fuller | officer: CFO and Executive V.P. | 55 WANDERWOOD WAY, SANDY UT 84092 |
Frederic J Winssinger | director | 2944 N 44TH STREET, SUITE 250, PHOENIX AZ 85018 |
David Mulham Mulham | officer: Chief Field Development Office | 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120 |
Paul A. Jones | officer: CFO | 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120 |
Xia Ding | director | 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120 |
Daniel A. Macuga | officer: Chief Communications Officer | 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120 |
Jim Brown | officer: Chief Production Officer | 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120 |
Brent Neidig | officer: CO & Man. Dir. of China | 3838 WEST PARKWAY BLVD., WEST VALLEY CITY UT 84120 |
J Scott Nixon | director | 757 EAST SOUTH TEMPLE, SUITE 150, SALT LAKE CITY UT 84102 |
Kevin Guest | officer: E.V.P. of Marketing | 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120 |
Joshua Foukas | officer: Chief Legal Officer | 3838 WEST PARKWAY BLVD., SALT LAKE CITY X1 84120 |
G Doug Iiekking | officer: VP of Finance | C/O USANA HEALTH SCIENCES INC, 3838 W PARKWAY BLVD, SALT LAKE CITY UT 84120 |
Walter Noot | officer: Chief Information Officer | 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120 |
Robert A Sinnott | officer: Chief Scientific Officer | 400 55 WATER STREET, VANCOUVER A1 V6B1A1 |
From GuruFocus
By PRNewswire • 08-31-2023
By GuruFocus Research • 10-24-2023
By PRNewswire • 08-14-2023
By PRNewswire • 07-12-2023
By PRNewswire • 12-04-2023
By PRNewswire • 01-23-2024
By PRNewswire • 08-16-2023
By PRNewswire PRNewswire • 05-25-2023
By PRNewswire • 06-22-2023
By PRNewswire • 11-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.